Anti-CD22 Immunotoxin (CAT-8015)
CAT-8015 is a closely related successor of CAT-3888, which demonstrated activity in clinical studies of hairy cell leukemia (HCL). CAT-8015 was developed in order to improve upon the activity of CAT-3888 in the treatment of a variety of CD22+ B cell malignancies. The new compound has shown an improvement in the cytotoxic activity, when compared with CAT-3888, against B-cell cancer cell lines and malignant cells isolated from patients with HCL, chronic lymphocytic lymphoma (CLL) and pediatric acute lymphocytic lymphoma (pALL).

Anti-IL5 receptor a MAb (MEDI-563)
MEDI-563 (previously known as BIW-8405), is a fully humanized afucosylated IgG1 anti-IL-5R alpha chain monoclonal antibody, derived from mice. It was developed by BioWa, Inc. through proprietary Potelligent ® technology that significantly enhances antibody-dependent cellular cytotoxicity. MEDI-563 neutralizes IL-5 activity and depletes tissue eosinophils in pre-clinical models with an acceptable toxicology profile. MEDI-563 has an identified specificity for the human IL-5 alpha receptor subunit found on eosinophils, which are believed to play a key role in the pathogenesis of asthma.

Anti-GM-CSFR a MAb(CAM-3001)
CAM-3001, a human IgG4 that specifically neutralizes granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) alpha chain, has potential in the treatment of rheumatoid arthritis (RA). Published data provides evidence for the role of GM-CSF in RA and is strong evidence for evaluating CAM-3001 in patients with the disease.

PIV3/RSV Vaccine (MEDI-534)
MEDI-534 is a live attenuated, intranasal, recombinant bovine parainfluenza virus type 3 (bPIV3) vaccine that has been genetically engineered to express the fusion (F) protein of the human respiratory syncytial virus (RSV); in addition, the F and hemagglutinin-neuraminidase (HN) genes of the bovine PIV3 have been replaced with the F and HN genes from a human PIV3 virus. MEDI-534 is being developed for the prevention of lower respiratory tract disease in young infants that is caused by RSV and PIV3.

RSV Vaccine (MEDI-559)
EDI-559 is an intranasal, recombinant, live attenuated, temperature sensitive respiratory syncytial virus (RSV) vaccine being developed, in conjunction with the National Institute of Allergy and Infectious Disease (NIAID), for the prevention of lower respiratory tract disease in young infants that is caused by RSV.

PIV3 Vaccine (MEDI-560)
MEDI-560 is an intranasal, recombinant live, attenuated, cold-adapted and temperature sensitive parainfluenza virus type 3 (PIV3) vaccine being developed in conjunction with the National Institute of Allergy and Infectious Disease (NIAID), for the prevention of lower respiratory tract disease in young infants that is caused by PIV3.

Pandemic Flu Vaccine
MedImmune has developed a prudent and comprehensive strategy to apply its unique live attenuated influenza vaccine technology to the development of pandemic vaccines, prioritizing the subtypes based on current epidemiology.

To assist national pandemic preparedness in the US, MedImmune has partnered with the National Institutes of Health (NIH) to prepare pandemic live, attenuated influenza (pLAIV) vaccines for all 16 subtypes and assess their safety and ability to stimulate an immune response in humans. MedImmune has also partnered with the US Department of Health and Human Services (HHS) to develop technologies for producing pLAIV in cell culture and in eggs. Seasonal LAIV attributes suggest that a pandemic LAIV formulation may be an important component of pandemic preparedness for both industrialized nations as well as developing countries.

S. Pneumoniae Vaccine
S. Pneumoniae vaccine is a program aiming to help elderly patients and is being advanced through a partnership between MedImmune and GlaxoSmithKline (GSK).